<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of electrolyte abnormalities in tumor lysis syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of electrolyte abnormalities in tumor lysis syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">Management of electrolyte abnormalities in tumor lysis syndrome</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1">Abnormality </td> <td class="subtitle1">Management recommendation </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Hyperphosphatemia </td> </tr> <tr> <td class="indent1" rowspan="7">Moderate, ≥2.1 mmol/L (6.5 mg/dL) </td> <td>Restrict phosphate intake (avoid IV and oral phosphate; limit dietary sources)</td> </tr> <tr> <td class="sublist1_start">Phosphate binders: </td> </tr> <tr> <td class="sublist1"><strong>Calcium acetate</strong><sup>*</sup> Adult: 2 to 3 tabs (1334 to 2668 mg) with each meal; or </td> </tr> <tr> <td class="sublist1"><strong>Calcium carbonate</strong>* Adult: 1 to 2 grams with each meal; Pediatric: 30 to 40 mg/kg with each meal; or </td> </tr> <tr> <td class="sublist1"><strong>Sevelamer<sup>¶</sup></strong> Adult: 800 to 1600 mg with each meal; Pediatric: 40 to 54 mg/kg with each meal; or </td> </tr> <tr> <td class="sublist1"><strong>Lanthanum carbonate </strong>Adult: 500 to 1000 mg with each meal<sup>Δ</sup>; or </td> </tr> <tr> <td class="sublist1"><strong>Aluminum hydroxide </strong>Adult: 300 to 600 mg with each meal; Pediatric: 12.5 to 37.5 mg/kg four times daily with meals; (avoid use in patients with renal insufficiency) </td> </tr> <tr> <td class="indent1">Severe </td> <td>Dialysis, CAVH, CVVH, CAVHD, or CVVHD</td> </tr> <tr> <td class="subtitle2" colspan="2">  </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Hypocalcemia, total serum calcium ≤1.75 mmol/L (7 mg/dL) or ionized calcium ≤0.8 mmol/L (3.2 mg/dL) </td> </tr> <tr> <td class="indent1">Asymptomatic </td> <td>No therapy</td> </tr> <tr> <td class="indent1" rowspan="2">Symptomatic </td> <td class="sublist1_start">Calcium gluconate administered slowly with ECG monitoring; patients with acute hypocalcemia and hyperphosphatemia should not be treated with calcium until the hyperphosphatemia is corrected (unless they have tetany or a cardiac arrhythmia from hypocalcemia) </td> </tr> <tr> <td class="sublist1"><strong>Calcium gluconate</strong><sup>◊</sup> Adult: 1 gram (10 mL of 10 percent solution); Pediatric: 50 to 100 mg/kg. Slow IV infusion (maximum 50 to 100 mg per minute) in large vein. May be repeated after 5 to 10 minutes if symptoms or ECG changes persist. </td> </tr> <tr> <td class="subtitle2" colspan="2">  </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Hyperkalemia<sup>§ </sup></td> </tr> <tr> <td class="indent1" rowspan="3">Moderate and asymptomatic, ≥6.0 mmol/L </td> <td>Avoid IV and oral potassium</td> </tr> <tr> <td>ECG and cardiac rhythm monitoring</td> </tr> <tr> <td><strong>Sodium polystyrene sulfonate</strong><sup>¥</sup> Adult: 15 to 30 grams orally; Pediatric: 1 gram/kg orally. Onset 1 to 2 hours. Repeat every 4 to 6 hours up to four times daily as needed based on repeat serum K+ level.</td> </tr> <tr> <td class="indent1" rowspan="12">Severe (&gt;7.0 mmol/L) and/or symptomatic </td> <td><strong>Same as above, plus:</strong></td> </tr> <tr> <td class="sublist1_start">To stabilize cardiac membranes: </td> </tr> <tr> <td class="sublist1">For patients with ECG changes (widening of the QRS complex or loss of p-waves but not peaked t-waves alone), <em>give calcium gluconate by slow IV infusion</em> to prevent life-threatening arrhythmias: </td> </tr> <tr> <td class="sublist2"><strong>Calcium gluconate </strong>Adult: 1 gram (10 mL of 10 percent solution); Pediatric: 50 to 100 mg/kg. Slow IV infusion (maximum 50 to 100 mg per minute) in large vein. May be repeated after 5 to 10 minutes if ECG changes persist. </td> </tr> <tr> <td class="sublist1_start">To temporarily shift potassium into cells: </td> </tr> <tr> <td class="sublist1">Give IV insulin and dextrose: </td> </tr> <tr> <td class="sublist2"><strong>IV insulin and dextrose </strong>Adult: regular insulin (10 units) IV plus 100 mL of a 50 percent dextrose solution (D50) IV; Pediatric: regular insulin (0.1 unit/kg) IV, plus 25 percent dextrose solution (D25) 0.5 gram/kg (2 mL/kg of D25) IV over thirty minutes. May be repeated after thirty to sixty minutes. Monitor fingerstick glucose closely. </td> </tr> <tr> <td class="sublist1">Sodium bicarbonate can be given to induce influx of potassium into cells if patient is acidemic. Sodium bicarbonate and calcium solutions should not be administered through the same line due to incompatibility. </td> </tr> <tr> <td class="sublist2"><strong>Sodium bicarbonate</strong> Adult: 45 to 50 mEq; Pediatric: 1 to 2 mEq/kg. Slow IV infusion over five to ten minutes. </td> </tr> <tr> <td class="sublist1">Beta 2 agonist inhalation: Albuterol per nebulisation or metered dose inhaler </td> </tr> <tr> <td class="sublist2"><strong>Albuterol</strong> Adult: 10 to 20 mg in 4 mL saline nebuilzed over 20 minutes or 10 to 20 puffs per metered dose inhaler over 10 to 20 minutes; Pediatric: 0.1 to 0.3 mg/kg per nebulisation. </td> </tr> <tr> <td>Dialysis</td> </tr> <tr> <td class="subtitle2" colspan="2">  </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Uremia (renal dysfunction) </td> </tr> <tr> <td rowspan="5">  </td> <td>Fluid and electrolyte management</td> </tr> <tr> <td>Uric acid and phosphate management</td> </tr> <tr> <td>Adjust renally excreted drug doses</td> </tr> <tr> <td>Dialysis (hemo- or peritoneal)</td> </tr> <tr> <td>Hemofiltration (CAVH, CVVH, CAVHD, or CVVHD)</td> </tr> </tbody></table></div><div class="graphic_lgnd">Pediatric dose should not exceed usual adult dose.</div><div class="graphic_footnotes">IV: intravenous; CAVH: continuous arterial-venous hemofiltration; CVVH: continuous veno-venous hemofiltration; CAVHD: continuous arterial-venous hemodialysis; CVVHD: continuous veno-venous hemodialysis; ECG: electrocardiogram.<br/>* Calcium-containing binders are generally preferred in presence of hypocalcemia; avoid if hypercalcemic.<br/>¶ Preferred binder in presence of hypercalcemia. <br/>Δ A pediatric dose of lathanum carbonate 7 mg/kg with each meal has been suggested based on limited experience. US FDA product information states pediatric use is not recommended. <br/>◊ 10% calcium gluconate (90 mg elemental calcium/10 mL) or 10% calcium chloride (270 mg elemental calcium/10 mL) can be used. Calcium gluconate is usually preferred because it is less likely to cause tissue necrosis if extravasated. For additional information refer to UpToDate topic on"Treatment of hypocalcemia".<br/>§ For additional information, refer to UpToDate topic on "Treatment and prevention of hyperkalemia in adults".<br/>¥ Patients receiving sodium polystyrene sulfonate should be monitored for the development of hypocalcemia and hypomagnesemia.</div><div class="graphic_reference">Data from: Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767.</div><div id="graphicVersion">Graphic 70281 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
